Health authorities in the United States on Tuesday recommended stopping the use of the Johnson & Johnson’s coronavirus vaccine, Reuters reported.
Hopes were high for the single-dose vaccine, however, it was recently reported that six females under the age of 50 years developed rare blood clots after receiving the shot.
The move adds to the challenges facing the vaccination process in general, including side effects and the efficacy against new variants.
Accordingly, Johnson & Johnson decided to delay introducing its vaccine to European markets.